Response
We would like to thank Van Noord and colleagues for their valuable comments regarding our article on the conversion and maintenance of sinus rhythm with dofetilide. 1 Regarding the success of cardioversion, as will be published in a correction, the percent of successful cardioversion for the dofetilide 500 g BID group was 81%, not 71%. As is seen in Table 2 from the article, 1 62 of 77 patients in the dofetilide 500 g group converted compared with 68 of 84 patients in the placebo group. Therefore, there was no difference in cardioversion for the dofetilide versus placebo groups. 1 In fact, 23 of these 62 patients in the dofetilide 500 g group also converted pharmacologically.
In response to Van Noord and colleagues' comment about the initial relapse rates over the first 2 weeks, we would like to offer the probabilities of remaining in sinus rhythm at 7, 14, and 30 days. At 7 days, these were 0.90, 0.93, 0.88, and 0.91 for the dofetilide 125 g, 250 g, and 500 g and placebo groups, respectively. At 14 days, the rates were 0.60, 0.69, 0.77, and 0.58, respectively. At 30 days, the rates were 0.51, 0.60, 0.69, and 0.47, respectively. These data demonstrate, as do the results of the study by Tieleman et al, 2 a separation of the probabilities after 7 days, indicating that dofetilide suppresses recurrence earlier than can be appreciated from the published figure.
Furthermore, the studies of verapamil and other antiarrhythmic drugs they mentioned used different definitions for successful cardioversion. Unfortunately, this is true of much of the cardioversion literature. Specifically, in the study by DeSimone et al 2 that they quoted, successful cardioversion was defined as 3 beats of sinus rhythm, compared with our definition of sinus rhythm for 24 hours.
It is likewise difficult to compare studies with widely differing patient populations. Specifically, our population consisted of 59% to 69% of patients with NYHA class II to III heart failure and structural heart disease compared with a predominantly hypertensive population in DeSimone et al's study 3 and few patients with significant heart disease in Tieleman et al's study. 2 In summary, the data support the use of dofetilide for both cardioversion and maintenance of sinus rhythm, especially because the drug has been shown to be safe, even in heart failure patients. 4 
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